Genetic
SCG101
SCG101 is a genetic therapy with 3 clinical trials. Currently 2 active trials ongoing.
Total Trials
3
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Active Trials
2(67%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Recruiting2
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
recruiting267%
unknown133%
Recent Activity
2 active trials
Showing 3 of 3
recruitingphase_1
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
NCT05417932
recruitingphase_1
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
NCT06617000
unknownphase_1
Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC
NCT05339321
Clinical Trials (3)
Showing 3 of 3 trials
NCT05417932Phase 1
A Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma
NCT06617000Phase 1
A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related
NCT05339321Phase 1
Autologous HBV-specific T Cell Receptor Engineered T Cells (TCR-T) in Patients With HBV-related Advanced HCC
All 3 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 3